Dilawari A, Zhang H, Shah M, Gao X, et al. US Food and Drug Administration Approval Summary: Trastuzumab Deruxtecan for the Treatment of Adult Patients With Hormone Receptor-Positive, Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2-Low or Human Epidermal Growth Factor Recep J Clin Oncol 2025 Aug 5:JCO2500812. doi: 10.1200/JCO-25-00812.
PMID: 40763319